Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $46 to $58.
October 27, 2023 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Equal-Weight rating on Blueprint Medicines and raises the price target from $46 to $58. This could potentially lead to an increase in the stock's price.
The raised price target by Barclays indicates a positive outlook for Blueprint Medicines. This could lead to increased investor confidence and potentially an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100